Sari Pesonen

Targovax (Finland) — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index1.9kcitations47works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(33), CAR-T cell therapy research(26), Cancer Research and Treatments(17), Viral Infectious Diseases and Gene Expression in Insects(10), RNA Interference and Gene Delivery(7)

Publications46 total

Anti-tumor specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)·2018· 3 citedOpen Access
Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model
Journal of Medical Virology·2018· 42 citedOpen Access
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
PLoS ONE·2017· 43 citedOpen Access
ASSOCIATION ADÉNOVIRUS/AGENTS CHIMIOTHÉRAPEUTIQUES POUR LE TRAITEMENT DU CANCER
2017
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
Journal for ImmunoTherapy of Cancer·2016· 17 citedOpen Access
Improving the efficacy of PDL1 blockade by combination with oncolytic vaccines
Annals of Oncology·2016Open Access
Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model
International Journal of Cancer·2016· 56 citedOpen Access
661. Synergistic Anti-Tumor Efficacy of Immunogenic Adenovirus ONCOS-102 and Standard of Care Chemotherapy in Preclinical Mesothelioma Model
Molecular Therapy·2016· 3 citedOpen Access
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
Journal for ImmunoTherapy of Cancer·2016· 198 citedOpen Access
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
OncoImmunology·2015· 40 citedOpen Access
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
Human Gene Therapy·2015· 22 citedOpen Access
An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors.
Journal of Clinical Oncology·2015· 1 cited
438. Oncolytic Immunotherapy for Treatment of Breast Cancer, Including Triple-Negative Breast Cancer
Molecular Therapy·2015Open Access
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8<sup>+</sup>T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
OncoImmunology·2015· 56 citedOpen Access
Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
Journal for ImmunoTherapy of Cancer·2015· 1 citedOpen Access
136 Tumor-infiltrating lymphocytes (TILs) following intratumoral administration of ONCOS-102 are associated with prolonged overall survival in last line solid tumor patients
European Journal of Cancer·2014
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8<sup>+</sup>T-cell response, prominent infiltration of CD8<sup>+</sup>lymphocytes and Th1 type polarization
OncoImmunology·2014· 48 citedOpen Access
Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
Molecular Therapy — Oncolytics·2014· 15 citedOpen Access
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans
International Journal of Cancer·2013· 44 cited
Ad3-hTERT-E1A, a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer
Molecular Therapy·2012· 85 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Akseli Hemminki(35), Anna Kanerva(21), Vincenzo Cerullo(20), Tuuli Ranki(15), Timo Joensuu(14), Elina Haavisto(11), Ari Ristimäki(10), Lotta Vassilev(10), Petri Nokisalmi(10), Kilian Guse(10), Kaarina Partanen(9), Iulia Diaconu(9), Lotta Kangasniemi(9), Kalevi Kairemo(8), Magnus Jäderberg(8), Gerd Bauerschmitz(8), Tiina Hakonen(7), Antti Vuolanto(7), Minna Oksanen(7), Maria Rajecki(7)